



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

June 8, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – June 06, 2021

TOTAL Cases Reported Since 1/22/20

33,193,680

NEW Cases Reported to CDC on 6/6/21

10,150

Change in 7-Day Case Average


-28.9%

Current 7-Day Case Average (5/31/21 - 6/6/21)

13,277

Prior 7-Day Case Average (5/24/21 - 5/30/21)

18,684



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – June 05, 2021

Patients Currently Hospitalized with COVID on 6/5/21

11,634

New Admissions on 6/5/21

1,687

Peak in New Admissions (1/5/21)

17,963

Change in 7-Day Average of New Admissions


-23.1%

Current 7-Day Average of New Admissions (5/30/21 - 6/5/21)

2,207

Prior 7-Day Average of New Admissions (5/23/21 - 5/29/21)

2,870



Daily Change in COVID-19 Deaths, US

January 22, 2020 – June 06, 2021

TOTAL Deaths Reported Since 1/22/2020

594,802

NEW Deaths Reported to CDC on 6/6/21

225

Change in 7-Day Death Average

-0.3%

Current 7-Day Death Average (5/31/21 - 6/6/21)


379

Prior 7-Day Death Average (5/24/21 - 5/30/21)

380

Forecasted Total Deaths by 6/26/21

601,000 to 614,000



New Nomenclature for Selected SARS-CoV-2 Variants

- **Alpha – B.1.1.7**
- **Beta – B.1.351**
- **Gamma – P.1**
- **Delta – B.1.617.2**
- **Epsilon – B.1.429**
- **Iota – B.1.526**



Update on the SARS-CoV-2 Delta Variant (B.1.617.2)

- Reported in 60 countries, including UK, USA
- Transmissibility appears greater than wild-type SARS-CoV-2 and B.1.1.7 (Alpha) variant
- May be associated with increased disease severity (hospitalization risk) compared to Alpha
- In lab tests, associated with modest decreased neutralization by sera from previously infected and vaccinated individuals compared to Alpha
- **2 doses of Pfizer vaccine and AstraZeneca vaccine effective against Delta variant. Reduced vaccine effectiveness after one dose.**



Effectiveness of COVID-19 Vaccines against the B.1.617.2 Variant

JL Bernal, M Ramsay et al.


- **2 weeks after 2nd dose, Pfizer-BioNTech vaccine 88% effective against symptomatic disease from B.1.617.2 (Delta) variant and 93% effective against B.1.1.7 (Alpha) variant**
- **2 doses of AstraZeneca were 60% effective against Delta and 66% effective against Alpha**
- **3 weeks after one dose, both vaccines were only 33% effective against symptomatic disease from Delta and ~50% effective against Alpha**

SARS-CoV-2 Delta Variant in the United Kingdom

- **Rapidly emerging as the dominant variant - >60%**
- **Replacing B.1.1.7 (Alpha variant)**
- **Peak transmission in the 12-to-20 years age group**
- **Poor protection after single dose of mRNA or AZ vaccine**



B.1.1.7 (Alpha) Variant Being Replaced by B.1.617.2 (Delta) Variant in U.K.



Source: Public Health England, June 3, 2021.



**The SARS-CoV-2 Delta variant
(B.1.617.2) now accounts for
>6% of sequenced cases in the
United States.**





THE WHITE HOUSE
WASHINGTON

WH.GOV